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Abstract
Bone metastasis occurs in advanced stages of breast cancer, worsening the quality of life and increasing the mortality of patients.
Current treatments for bone metastasis are only palliative, and efficient therapeutic targets need to be still identified. MicroRNAs
(miRNAs) are a large class of small non-coding RNAs that regulate gene expression within cells. Interestingly, the expression of
certain miRNAs has been associated with several stages of bone metastasis progression, highlighting the importance of these
small RNAs during the course of the metastatic disease. In this review, we aim to summarise the most recent findings onmiRNAs
and their mRNA targets in driving breast cancer bonemetastasis. Furthermore, we discuss the possibility to use miRNAs as direct
therapeutic targets or as advanced therapies for breast cancer bonemetastasis, as well as their potential as predictive biomarkers of
bone metastasis for an early diagnosis and a better tailoring of therapies for cancer patients.
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Introduction
Bone metastasis is a frequent complication of breast cancer [1,
2]. Bone metastasis results from the spreading of primary
cancer cells in the bonemicroenvironment [3]. In bone, cancer
cells need to adapt to a new micro-environment, which is
highly vascularised, and to interact with bone resident cells
(osteoblasts, osteocytes and osteoclast) as well as other cells
present in the bone marrow (e.g. immune system cells) [3].
The presence of a permissive soil called “pre-metastatic
niche” in the bone micro-environment and osteomimicry—
the process for which “foreigner” cells mimic bone resident
cells—are key steps for cancer cells to successfully seed in
bone [4, 5]. Interestingly, cancer cells homing in bone can stay
dormant for a long time, usually by exiting and re-entering in a
low-proliferative state, until they eventually receive a signal
that triggers their reactivation [6]. Once cancer cells start to
proliferate, they first form undetectable micro-metastases,
which then evolve in clinically detectable bone metastases
[7]. As a consequence of the presence of a macro-metastasis
or multiple metastases in bone, cancer patients suffer of bone
fractures, spinal cord compression, bone pain and disability
due to a weaker bone structure [8]. About 30% of breast can-
cer patients with advanced disease develop metastases, with a
high prevalence of metastases to the bone compared to other
distant sites [9]. Breast cancer patients with bone metastasis
usually present osteolytic lesions (bone destruction) in the
vertebrae and weight-bearing bones, which may lead to path-
ological fractures that require surgical interventions [10].
Current treatments for bone metastasis involve systemic ther-
apies, such as chemotherapy and endocrine treatments, to
slow down the proliferation rate of cancer cells, bone targeted
agents, such as bisphosphonates or Denosumab (amonoclonal
antibody), to inhibit excessive cancer-associated bone destruc-
tion and the use of bone seeking radionucleotides [11].
However, although these treatments can improve the quality
of life of cancer patients with bone metastasis, they are only
palliative [11], and there is therefore a need for novel
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therapeutic or diagnostic interventions to prevent bone metas-
tasis formation.
MicroRNAs (miRNAs) are a large class of short non-
coding RNAs that regulate gene expression within cells. The
biogenesis of miRNAs is complex and requires the activity of
different enzymes to obtain a mature form that complexes
with Argonaute proteins (AGO) to form an effector complex
called RNA-induced silencing complex (RISC). RISC recog-
nises complementary sequences with the ‘guide’ miRNA se-
quence on mRNAs targets to mediate their degradation [12].
Of note, the post-transcriptional regulation of miRNAs is very
complex within cells since one single miRNA can target hun-
dreds of different mRNA targets. Moreover, the expression of
a specific mRNA can be regulated by several different
miRNAs [13]. MiRNA regulation activity in cells is therefore
of crucial importance to maintain physiological functions, and
their dysregulation has been observed in cancer cells [14]. By
definition, oncomiRs are miRNAswhich expression promotes
tumorigenesis by inhibiting the translation of oncosuppressor
genes, while oncosuppressor miRNAs have an opposite role
inhibiting oncogene expression [15]. The expression of
oncomiRs or oncosuppressor miRNAs is often time related,
and they regulate and promote different steps of tumour pro-
gression from early to advanced stages. In bone metastasis,
several miRNAs have been reported to act as drivers of the
molecular changes within cells [16]. The expression of some
miRNAs has been associated with an invasive and aggressive
phenotype of cancer cells that promote their dissemination, or
with their preference to metastasise in bone. Here, we will
discuss the most recent findings over the last 5 years on
miRNAs that regulate the formation and development of
breast cancer bone metastasis (Table 1, Fig. 1), and how our
current knowledge on miRNAs can be used for innovative
therapies and/or development of diagnostic tools.
OncomiRs in Breast Cancer Bone Metastasis
miR-10b
MiR-10b has been identified as an important oncomiR asso-
ciated with the metastatic potential of breast cancer cells, pro-
moting tumour cell migration and invasion to secondary or-
gans, such as lung [17]. In early stages of breast cancer me-
tastasis progression, miR-10b promoted by TWIST1 inhibits
the expression of the transcription factor homeobox D10, thus
leading to the over-expression of a pro-metastatic factor,
RHOC, in cancer cells [17]. Recently, it has also been dem-
onstrated that, in a bone-seeking sub-population of metastatic
breast cancer cells, TWIST1 promotes bone metastasis forma-
tion [18]. Interestingly, the transfection of a miR-10b
antagomiR in these TWIST1-expressing bone-seeking breast
cancer cells inhibits the development of experimental bone
metastasis in mice [18]. These findings should encourage the
development of targeted therapies that specifically inhibit
TWIST1 and/or miR-10b expression levels in cancer cells in
order to reduce the risk of bone metastasis formation in breast
cancer patients.
miR-21
The oncomiR miR-21 is highly expressed in several cancers
and associated with poor prognosis in patients with cancer. In
breast cancer, miR-21 promotes metastatic breast cancer cells
to colonise bone and form macro-metastasis [19].
Mechanistically, lysophosphatidic acid (LPA1), a bioactive
lipid that promotes cancer progression and bone metastasis,
stimulates miR-21 expression in breast cancer cells via a
LPA1/Pi3K/ZEB1-dependent signalling pathway [19]. The in-
hibition of miR-21 expression results in a decreased capacity
Table 1 MiRNAs controlling
breast cancer bone metastasis
formation
OncomiRs
MiRNA name: miR-10b Validated targets: HoxD10 References: [17, 18]
miR-21 Pten, Pdcd4, Spry2 [19]
miR-214-3p Traf3 [20–22]
miR-218-5p Sost, Sfrp2 [23, 24]
miR-940 [25]
Oncosuppressor miRNAs









of breast cancer cells to migrate in vitro, and a decrease of
bone metastasis formation in vivo [19]. A similar effect is
obtained with the silencing of LPA1 or ZEB1 reinforcing the
evidence that LPA1 and ZEB1 are upstream regulators of
miR-21 [19]. Thus, by acting on multiple targets on this path-
way is possible to prevent metastatic cells to migrate to bone.
miR-214-3p
The osteoclast-derived miR-214-3p contributes to breast
cancer bone metastasis [20]. Metastatic breast cancer cells
usually induce osteolytic lesions by increasing osteoclast-
mediated bone resorption, thereby causing excessive bone
destruction [16]. The expression level of miR-214-3p in
pathological bone fracture specimens from breast cancer
patients with bone metastases is higher than that in breast
cancer patients without osteolytic bone metastasis and
even more elevated in comparison to miR-214-3p levels
in bone fracture specimens from cancer-free patients [20].
In miR-214-3p knockout nude mice, the osteoclast activity
is reduced, and the osteolytic bone metastasis development
after breast cancer cell inoculation is prevented in compar-
ison to normal nude mice bearing breast cancer bone me-
tastases [20]. MiR-214-3p directly targets Traf3, an inhib-
itor of osteoclast differentiation, thereby promoting
osteoclast-mediated bone resorption [20]. Interestingly,
the inhibition of the osteoclastic miR-214-3p has a thera-
peutic effect in animal models by attenuating the extent of
osteolytic bone metastases [20]. Of note, osteoclast-
derived exosomal miR-214-3p can also transfer to osteo-
blasts to inhibit bone formation [21], and tumour-derived
miR-214 promotes breast cancer cell dissemination in vivo
[22]. Collectively, these studies [20–22] strongly suggest
that inhibition of miR-214-3p may be a strategy for treating
osteolytic lesions in metastatic breast cancer.
miR-218-5p
MiR-218-5p is an oncomiR that favours the metastatic dis-
semination of triple-negative breast cancer (TNBC) cells in
bone [23]. MiR-218-5p expression levels are increased in
bone metastasis patients’ samples in comparison to healthy
bone controls and primary breast tumours [23], suggesting
its involvement in bone metastasis progression. In line with
these findings, the metastatic MDA-MB-231 cell line shows
increased levels of miR-218-5p in comparison to a non-
malignant cell line (MCF10A) and a non-metastatic cell line
(MCF7) [23]. The over-expression of miR-218-5p in MDA-
MB-231 cells increases cell proliferation in vitro, whereas
miR-218-5p downregulation results in a reduced proliferation
of MDA-MB-231 cells in vitro and reduced tumour growth
and osteoclast activity in vivo [23]. MiR-218-5p directly tar-
gets SOST and SFRP2, two inhibitors of the Wnt-signalling
pathway, elucidating the mechanism by which this miRNA
operates within cancer cells [23]. Also, low expression levels
of miR-218-5p results in a downregulation of genes involved
with bone metastasis and osteoclast activation, suggesting that
miR-218-5p mediates the acquisition of osteomimicry proper-
ties of metastatic cells, and thus favouring their adaptation in
bone [23]. Furthermore, exosomal miR-218 produced by
MDA-MB-231 cells directly downregulates collagen type I
alpha 1 (COL1A1) in MC3T3 pre-osteoblastic cells, which
leads to a diminished type I collagen deposition by mature
osteoblasts in vitro [24].
miR-940
The oncomiR miR-940—secreted by cancer cells—induces
osteoblastic bone metastasis [25]. MiR-940 is another good
example of miRNAs originating from cancer cells that is re-
sponsible for modifications of bone remodelling. As afore-
mentioned for miR-218 [23], miRNAs can be secreted from
Fig. 1 MiRNAs expression in
breast cancer cells. Breast cancer
cells with a different metastatic
potential express different
miRNAs that contribute to their
phenotype. Here, we show a
schematic representation of the
expression of those miRNAs in
poorly or highly metastatic breast
cancer cells
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cells—commonly, via exosomes—and mediate the cross-talk
between cancer cells and bone microenvironment [16]. MiR-
940 is highly expressed in exosomes from prostate cancer cell
lines that induce an osteoblastic lesion in comparison to cells
lines that cause osteolytic lesions [25]. The exosomal cancer
cell-derived miR-940 is able to promote the osteogenic differ-
entiation of human mesenchymal stem cells from which oste-
oblast lineage originates [25]. Interestingly, when miR-940 is
experimentally over-expressed in a breast cancer cell line, the
MDA-MB-231, which usually induces osteolytic lesions in
animals, these cells induce osteoblastic lesions in vivo [25].
This study clearly shows how a single miRNA, produced by
cancer cells, once secreted within exosomes, can affect the
activity/maturation of normal recipient cells in the bone mi-
croenvironment. These data suggest that not only miRNA
dysregulations within cancer cells are important to study but
also the alteration of circulating miRNA levels that can wors-
en pathological conditions, as shown in this study, or that
could prepare a fertile soil for the seeding of disseminated
cancer cells in distant organs.
Oncosuppressor miRNAs in breast cancer
bone metastasis
miR-30 family (miR-30s)
The five members of the miR-30 family (miR-30s)—miR-
30a, miR-30b, miR-30c, miR-30d and miR-30e—act as
oncosuppressors in breast cancer [26]. MiR-30s low expres-
sion levels in primary breast tumours are associated with poor
clinical outcomes [26]. Additionally, miR-30s expression
levels have been reported to be lower in human bone-tropic
MDA-B02 breast cancer cells, a sub-population of the paren-
tal MDA-MB-231 cells, and in the BC-M1 cells, a dissemi-
nated tumour cell line isolated from the bone marrow of a
breast cancer patient, when compared to MDA-MB-231 cells
[26]. Interestingly, the forced expression of miR-30s inMDA-
B02 cells impedes both skeletal tumour progression and bone
destruction in animal models [26]. MiR-30s are negative reg-
ulators of key oncogenes and pro-osteoclastic factors that con-
tribute to bone metastasis development (IL-8, IL-11, DKK-1,
RUNK2, CDH11, CTGF and integrins ITGA5 and ITGB3)
[26]. Cdh11 or Itga5 silencing in bone-tropic breast cancer
cells recapitulates the inhibitory effect of miR-30s on bone
metastasis formation in animal models, further confirming that
these effector oncogenes are regulated by miR-30s [26].
A recent study has reported that high circulating miR-30b-
5p levels are detected in patients with metastatic breast cancer
(n=12) compared to patients with localised breast cancer
(n=20) [27]. Higher miR-30b-5p levels in metastasis speci-
mens (n=22), including bone metastasis, were also observed
when compared to matched primary tumours (n=16) [27]. The
authors [27] hypothesised that, at an early stage of metastasis
development, miR-30b-5p is downregulated inmetastatic can-
cer cells undergoing epithelial-to-mesenchymal transition
(EMT), whereas it is re-expressed in later stages of the meta-
static process, when cancer cells undergo mesenchymal-to-
epithelial transition (MET), suggesting a time-dependent role
for miR-30b-5p in breast cancer. However, the limited num-
ber of patients evaluated in this study clearly prevents any firm
conclusion. Furthermore, accumulating evidence demon-
strates that miR-30 family members act as oncosuppressor
genes in breast cancer progression and metastasis [26, 28,
29]. Nevertheless, this study [27] highlights the potential use
ofmiRNAs as biomarkers—beyond their potential use as ther-
apeutic agents or targets—taking in account that miRNAs are
stable and can be easily detected in the circulation of cancer
patients [16].
miR-34a
MiR-34a attenuates tumour growth in TNBC, the most lethal
subtype of breast cancer that often metastasises to distant or-
gans including bone [30, 31]. MiR-34a expression is lost in
TNBC cells, in particular in claudin-low TNBC breast cancer
cell lines, which express mesenchymal and stem cell markers,
as well as in primary TNBC tumour specimens [30].
Moreover, when compared to MDA-MB-231 cells, very low
miR-34a-5p expression levels are observed in 1833 cells, a
bone-metastatic sub-population of the MDA-MB-231 paren-
tal cell line [30]. The forced expression of miR-34a in MDA-
MB-231 and 1833 breast cancer cells inhibits cell proliferation
and invasion, activates cell senescence, and promotes sensi-
tivity to dasatinib, a BCR-ABL and Src tyrosine kinase inhib-
itor [30, 32]. Systemic miR-34a administration reduces sub-
cutaneous or orthotopic growth of induced tumours in animal
models [30]. In human, a phase-I clinical trial has been con-
ducted and patients with refractory advanced solid tumours
(n=47) were treated with escalating doses of a miR-34a mimic
encapsulated in lipid nanoparticles, called MRX34 [33].
Although this clinical trial was terminated prematurely due
to serious adverse events in patients, including infusion-
associated events that could be linked to the liposome carrier,
it showed preliminary evidence of an anti-tumour activity
[29]. A better strategy of delivery should be investigated to-
gether with the possibility of a combined therapy with other
miRNAs or approved drugs to increase the efficiency of treat-
ments for the still incurable TNBC.
miR-124
MiR-124 has been largely investigated for its role as a tumour
suppressor in different types of cancer and, more recently, as a
critical factor in breast cancer metastasis in bone [34]. MiR-
124 expression is decreased in human breast cancer cell lines
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in comparison to normal human mammary tissue, and further
decreased in invasive breast cancer cell lines, including bone-
seeking cancer cells, compared to their non-invasive counter-
part [34]. The clinical relevance of miR-124 is further con-
firmed by the fact that miR-124 expression—evaluated by in
situ hybridisation—is reduced in primary breast tumours in
comparison to paired non-tumour tissues, and even more re-
duced in metastatic bone tissues [34]. The forced expression
of miR-124 in bone-tropic breast cancer cells reduces bone
metastasis formation and the extent of osteolysis in vivo,
whereas miR-124 inhibition in non-invasive cancer cells pro-
motes bone metastasis formation [34]. Mechanistically, the
downregulation of miR-124 expression levels result in in-
creased levels of its direct target IL-11, which acts as an effector
to promote osteoclastogenesis and bone metastasis formation
[34].
miR-125b
MiR-125b regulates key players of the bone microenviron-
ment with a role in breast cancer bone metastasis formation
[35]. In bone, the hypoxia inducible factor-1 alpha (HIF1A)
has a promoting effect on breast cancer metastasis by upreg-
ulating prostaglandin endoperoxide synthase-2 (PTGS2, also
known as COX-2) [35]. The forced expression ofmiR-125b in
bone-tropic human 1833 breast cancer cells reduces bone me-
tastasis development by downregulating ETS1—a player for
the invasive program of cancer cells—and the extent of
osteolytic lesions in vivo [35]. Interestingly, a stronger inhib-
itory effect is observed when the forced expression of miR-
125b is combined with the treatment of animals with the che-
motherapeutic agent NS-398, an inhibitor of the pro-
tumorigenic factor PTGS2 [35]. In vitro, miR-125b expres-
sion increases the expression of E-cadherin, an epithelial cel-
lular marker, and it prevents MMP2 and vimentin expression,
two mesenchymal cellular markers [35]. The authors [35]
suggest that miR-125b might affect the interaction between
ETS1 and HIF1A, thus impairing (directly and/or indirectly)
PTGS2. A combined therapeutic approach NS-398/miR-125b
needs further validations but seems promising.
miR-135 and miR-203
MiR-135 andmiR-203 are two oncosuppressors of breast cancer
and metastatic bone disease [36]. In breast, miR-135 and miR-
203 are highly expressed in normal mammary epithelial cells,
while they are poorly expressed in bone metastasis specimens of
breast cancer patients in comparison to healthy bone [36].
Moreover, miR-135 and miR-203 are highly expressed in non-
metastatic MCF-7 breast cancer cells and poorly expressed in
metastatic MDA-MB-231 breast cancer cells [36]. The forced
expression of miR-135 and miR-203 in MDA-MB-231 cells
suppresses their migratory properties in vitro by downregulating
genes involved in cell motility (Rock, Cd44 and Ptk2) [36].
In vivo, the ectopic expression of miR-135 and miR-203 in
MDA-MB-231 cells reduces the size of primary tumours and
the spontaneous formation of metastases, including bone metas-
tases [36]. MiR-135 and miR-203 expression also protects
against the formation of osteolytic lesions in metastatic animals
by directly targeting RUNX2 in MDA-MB-231 cells, a tran-
scription factor that promotes early stages of tumour progression
and enhances the formation of osteolytic lesions in animals bear-
ing bonemetastases [36].MiR-135 also directly targets Smad5, a
component of the BMP signalling pathway, which consequently
reduces the expression of a BMP-2 downstream gene, Id2 [36].
Together, these findings pointing out two different molecular
mechanisms that can explain, at least in part, the role of miR-
135 and miR-203 as oncosuppressors in breast cancer bone
metastasis.
miR-205
MiR-205 mediates a molecular mechanism involved in breast
cancer bone metastasis [37]. Transglutaminase-2 (TG2) in-
duces EMT in various tumours, and its overexpression in hu-
man MCF-7 breast cancer cells (MCF7/TG2-C277S) pro-
motes bone metastasis formation in nude mice [37].
Interestingly, TG2 directly targets miR-205 [37]. The forced
expression of miR-205 in MCF7/TG2-C277S cells drastically
inhibits bone metastasis formation in vivo, and suppresses the
expression of ZEB1—an EMT-related factor—normally in-
duced by TG2 in vitro [37]. Of note, miR-205 (like miR-
30s) also targets the integrin ITGA5, which plays an essential
role in mediating breast cancer bone metastasis formation [26,
38]. The inhibition of TG2 or ITGA5 and/or the expression
rescue of miR-205 could therefore be potential therapeutic
approaches for the treatment of metastatic breast cancer pa-
tients with a TG2 dysregulation [37].
miR-429
MiR-429 is a member of the miR-200 family, which members
are known for their oncosuppressor roles in cancer progres-
sion [39]. Expression levels of miR-429 are low in bone tis-
sues from metastatic breast cancer patients in comparison to
primary tumour tissues, andmiR-429 low expression positive-
ly correlates with poor bone metastasis-free survival of breast
cancer patients [40]. The conditioned medium from a bone
metastatic sub-population of MDA-MB-231 cells, the 231-B
cell line, that artificially over-expresses miR-429, promotes
OPG and reduces RANKL expression levels in MC3T3-E1
osteoblastic cells in comparison to control [40], suggesting
that this miRNA promotes osteogenic differentiation
in vitro. MiR-429 also acts on osteoclasts by directly targeting
CrkL (v-CRK avian sarcoma virus CT10-homolog-like) and
decreasing MMP-9 expression, which results in the inhibition
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of osteoclast differentiation in vitro [40]. In vivo, animals
bearing 231-B breast cancer cells overexpressing miR-429
have less bone metastatic lesions than animals bearing paren-
tal cancer cells [40]. It is suggested that miR-429 and CrkL
could be used as biomarkers for predicting bone metastasis in
breast cancer patients at an early stage.
Concluding Remarks
MicroRNAs (miRNAs) are key regulators of the formation
and progression of breast cancer bone metastasis. MiRNAs
act at different levels within metastatic breast cancer cell—in
situ regulation—or affecting the differentiation and activity of
bone resident cells when they physically interact with them or
at long distance. In fact, the expression of specific miRNAs
can be altered in bone-metastatic breast cancer cells and en-
hance cell migratory and proliferative properties as well as
drug-resistance or stem-like phenotypes to promote the
seeding and adaptation of cancer cells in bone. Additionally,
breast cancer-derived circulating miRNAs can act at long dis-
tance to educate and remodel the bone microenvironment
making it more permissive for the seeding of disseminated
cancer cells, and disseminated cancer cells in bone can then
physically interact with bone cells and alter their physiological
activities in order to further sustain cancer cell growth.
Since the role of miRNAs in bone metastasis is very cen-
tral, it has been proposed to rescue their expression levels
when the miRNA is downregulated or inhibit their expression
levels once upregulated in metastatic breast cancer cells, or to
modulate expression levels of circulating miRNAs.
Experimentally, it has been proven that, by manipulating even
a single miRNA, it is possible to modify the phenotype of
cancer cells or modify their effects on the bone microenviron-
ment. However, while these experimental procedures are very
effective, we are still far to have an efficient delivery method
to treat cancer patients with a ‘miRNA therapy’. The phase-I
trial with MRX34 was a partial success, and new delivery
methods must be explored. Furthermore, since miRNAs are
stable in biological fluids and easily detected, they could be
used as diagnostic/prognostic tools in the clinic to predict
early relapse or response to specific treatments. Hopefully,
in the forthcoming years, the exciting field ofmiRNA research
will progress, and miRNAs will be part of an armamentarium
of advanced and personalised therapies for breast cancer pa-
tients at high risk of relapse in bone.
Summary
The over-expression of specific miRNAs (e.g.miR-10b, miR-
21 and miR-218-5p) or their downregulation (e.g miR-30s,
miR-34a, miR-124, miR-125b, miR-135, miR-203, miR-205
and miR-429) in breast cancer cells promotes the formation of
metastasis in bone [17, 19, 23, 26, 30, 34–37, 40].
MiRNAs released by bone cells (e.g. the osteoclast-derived
miR-214-3p) or breast cancer cells (e.g. miR-940) can affect
bone metastasis formation [16, 25].
A ‘miRNA therapy’ with a miRNA mimic (MRX34) has
been evaluated in a phase-I trial, but adverse effects have been
reported, likely due to the liposome carrier [33]. Better strat-
egies of miRNA delivery should be explored.
MiRNAs can be detected in the biofluids (e.g. serum) of
breast cancer patients and can be used as diagnostic bio-
markers [27].
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